[Form 4] Intellia Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Intellia Therapeutics EVP and Chief Medical Officer David Lebwohl reported a sale of common stock that was carried out solely to cover taxes on recently vested restricted stock units. On January 5, 2026, he sold 11,903 shares of Intellia Therapeutics common stock at $9.21 per share in a mandatory "sell-to-cover" transaction tied to RSUs that vested on January 1, 2026. After this transaction, Lebwohl beneficially owned 121,249 shares of Intellia common stock. This total includes 1,022 shares and 1,264 shares that were previously acquired through the company’s 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively.

Insider Trade Summary

Net Seller: 11,903 shares ($109,627)

Net Sell 1 txn

Insider Lebwohl David

Role EVP, Chief Medical Officer

Sold 11,903 shs ($110K)

Type	Security	Shares	Price	Value
Sale	Common Stock	11,903	$9.21	$110K

Holdings After Transaction: Common Stock — 121,249 shares (Direct)

Footnotes (1)

1. Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person. Includes 1,022 and 1,264 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lebwohl David

(Last) (First) (Middle)

C/O INTELLIA THERAPEUTICS, INC.

40 ERIE STREET; SUITE 130

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/05/2026		S(1)		11,903	D	$9.21	121,249(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person.

2. Includes 1,022 and 1,264 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively.

	James Basta, attorney-in-fact	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NTLA EVP and CMO David Lebwohl report?

David Lebwohl reported a sale of 11,903 shares of Intellia Therapeutics common stock on January 5, 2026 at a price of $9.21 per share.

Why did NTLA executive David Lebwohl sell 11,903 shares of stock?

The 11,903-share sale was a mandatory "sell-to-cover" transaction to satisfy his tax withholding obligations upon the vesting of RSUs on January 1, 2026, and was not a voluntary trade.

How many Intellia Therapeutics (NTLA) shares does David Lebwohl hold after this Form 4 transaction?

Following the reported sale, David Lebwohl beneficially owned 121,249 shares of Intellia Therapeutics common stock in direct ownership.

What is David Lebwohl’s role at Intellia Therapeutics (NTLA)?

David Lebwohl is an officer of Intellia Therapeutics, serving as EVP, Chief Medical Officer, and he is not a director or 10% owner.

Were employee stock purchase plan shares included in Lebwohl’s NTLA holdings?

Yes. His 121,249 beneficially owned shares include 1,022 shares and 1,264 shares acquired under the 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively.

Was the January 5, 2026 NTLA stock sale a discretionary trade by David Lebwohl?

No. The filing states the sale was a mandatory tax-related "sell-to-cover" linked to RSU vesting and does not represent a volitional trade by David Lebwohl.